Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
BRISBANE, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced new clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS trial in patients with IgA nephropathy (IgAN) and first-time results from a post-hoc analysis of the Phase 2 APRIL-SLE study in patients with systemic lupus erythematosus (SLE). These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.
